SS-31 (Elamipretide) is the only mitochondria-targeted peptide with significant human clinical trial data — Phase 2 and Phase 3 studies across multiple conditions including heart failure, primary mitochondrial myopathy, and age-related macular degeneration.

SS-31 (Elamipretide) is the only mitochondria-targeted peptide with significant human clinical trial data — Phase 2 and Phase 3 studies across multiple conditions including heart failure, primary mitochondrial myopathy, and age-related macular degeneration. While most peptides work by binding cell-surface receptors and triggering signaling cascades, SS-31 does something fundamentally different: it embeds itself in the inner mitochondrial membrane and stabilizes cardiolipin, the phospholipid that holds the electron transport chain together.

This mechanism sets SS-31 apart from every other compound in the longevity and mitochondrial research space. NAD+ precursors like NMN and NR provide substrates for energy production. CoQ10 serves as an electron carrier. But SS-31 protects the physical structures that make mitochondrial energy production possible in the first place. When cardiolipin degrades — as it does progressively with aging, oxidative stress, and mitochondrial disease — ATP production declines, reactive oxygen species spike, and cells enter a slow descent into dysfunction. SS-31 addresses this at the structural level.

How Does SS-31 Target Mitochondria?

SS-31 — also known as Elamipretide, MTP-131, or Bendavia — is a synthetic tetrapeptide with the sequence D-Arg-Dmt-Lys-Phe-NH₂. It was developed by Hazel Szeto and Peter Schiller at Weill Cornell Medical College and is named after the Szeto-Schiller (SS) peptide series. The alternating cationic (D-Arg, Lys) and aromatic (Dmt, Phe) residues give SS-31 a strong affinity for cardiolipin, which carries a negative charge on the inner mitochondrial membrane.

The targeting specificity is remarkable. SS-31 concentrates in mitochondria at 1,000 to 5,000 times the extracellular concentration — a level of organelle-specific accumulation that is rare for any compound, let alone a small peptide. Once at the inner mitochondrial membrane, SS-31 interacts with cardiolipin at the contact points between electron transport chain complexes. Cardiolipin is not merely a structural component — it is essential for the proper function of Complex I, Complex III, Complex IV, and ATP synthase. It stabilizes the supercomplex assemblies (respirasomes) that enable efficient electron transfer and minimize electron leak.

When cardiolipin is oxidized or degraded, electron transport becomes less efficient: more electrons leak from the chain and react with molecular oxygen to form superoxide and other reactive oxygen species (ROS). This creates a destructive feedback loop — ROS damage more cardiolipin, which causes more electron leak, which produces more ROS. SS-31 interrupts this cycle by stabilizing cardiolipin structure, maintaining respirasome integrity, reducing electron leak, and thereby lowering ROS production at the source rather than scavenging ROS after they form.

What Does the SS-31 Clinical Trial Data Show?

SS-31 has progressed through multiple clinical trials — a level of human evidence that distinguishes it from most compounds in the mitochondrial research space.

Heart failure trials (EMBRACE): The EMBRACE-STEMI Phase 2a trial evaluated SS-31 in patients with acute ST-elevation myocardial infarction. Participants received intravenous elamipretide before and during percutaneous coronary intervention. The study demonstrated feasibility and safety, with signals of reduced infarct size in treated patients. Cardiac ischemia-reperfusion injury involves massive mitochondrial dysfunction and ROS production — exactly the pathology SS-31’s mechanism addresses. The results provided proof-of-concept that mitochondrial protection during acute cardiac events is achievable with a peptide-based approach.

Barth syndrome (TAZPOWER): The most clinically advanced program for SS-31 is in Barth syndrome, a rare genetic disorder caused by mutations in the tafazzin gene that impair cardiolipin remodeling. The TAZPOWER Phase 3 trial evaluated elamipretide in Barth syndrome patients and demonstrated improvements in the 6-minute walk test — a standard endpoint for functional capacity. SS-31 received FDA approval for Barth syndrome under the brand name Forzinity at a dose of 40 mg subcutaneously once daily, making it the first mitochondria-targeted therapy approved for any condition.

Skeletal muscle aging: A Phase 2 study in older adults evaluated SS-31’s effects on skeletal muscle energetics. Using phosphorus-31 magnetic resonance spectroscopy (³¹P-MRS) to measure ATP production rates, researchers found that elamipretide improved mitochondrial ATP synthesis in aged skeletal muscle — providing direct bioenergetic evidence that SS-31 can reverse age-related mitochondrial decline in human tissue. This study is particularly important for the longevity research community because it demonstrates measurable bioenergetic improvement, not just clinical symptom changes.

Age-related macular degeneration: The ReCLAIM Phase 1/2 studies in dry age-related macular degeneration (AMD) showed preliminary signals of ellipsoid zone preservation — a structural biomarker of photoreceptor mitochondrial health. The ReNEW Phase 3 trial is evaluating elamipretide for dry AMD using ellipsoid zone area loss as its primary endpoint. Retinal photoreceptors have among the highest mitochondrial density of any cell type, making them particularly vulnerable to cardiolipin-mediated dysfunction.

How Does SS-31 Compare to MOTS-C and Other Mitochondrial Peptides?

The mitochondrial peptide category includes several compounds with distinct mechanisms. Understanding these differences is essential for researchers designing studies that target different aspects of mitochondrial function. PSPeptides carries both SS-31 and MOTS-C, the two most studied mitochondrial peptides, each addressing mitochondrial biology through a different pathway.

The SS-31 and MOTS-C comparison is particularly relevant because researchers frequently ask whether they serve the same purpose. They do not. SS-31 addresses mitochondrial structure — stabilizing the physical membrane architecture required for electron transport. MOTS-C addresses mitochondrial signaling — activating AMPK pathways that regulate cellular energy metabolism, glucose uptake, and metabolic homeostasis. The two mechanisms are complementary rather than redundant, which is why some researchers study them together in protocols that target both structural integrity and metabolic signaling simultaneously.

For researchers exploring the broader longevity peptide category, epitalon targets a different dimension of aging entirely — telomere biology and pineal melatonin restoration — providing yet another complementary mechanism for age-related research.

SS-31 and Neurodegenerative Research

Beyond cardiac and skeletal muscle applications, SS-31 has attracted attention in neurodegenerative disease research. The brain consumes approximately 20% of the body’s total energy despite comprising only 2% of body weight, making neurons exquisitely sensitive to mitochondrial dysfunction. Preclinical studies have demonstrated that SS-31 crosses the blood-brain barrier and concentrates in neuronal mitochondria, where it stabilizes cardiolipin and reduces ROS production in brain tissue.

Animal model data in Alzheimer’s disease shows that SS-31 reduces amyloid-beta-induced mitochondrial dysfunction, improves synaptic plasticity markers, and decreases neuroinflammation. These effects are mechanistically consistent: amyloid-beta directly damages cardiolipin and disrupts electron transport chain supercomplex assembly — exactly the pathology SS-31 is designed to address. While no human clinical trials have evaluated SS-31 specifically for neurodegeneration, the neuroprotective mechanism is well-supported by published preclinical data and extends the compound’s relevance beyond the cardiac and musculoskeletal domains.

For researchers studying neuroprotective peptides through different mechanisms, compounds like semax (BDNF-mediated neuroprotection) and selank (GABAergic anxiolysis with neurotrophic effects) target cognitive function through neurotransmitter and growth factor pathways rather than mitochondrial membrane protection. SS-31’s unique contribution to the neuroscience research toolkit is its ability to address the bioenergetic foundation that all neuronal function depends upon. This structural approach to neuroprotection remains unmatched by any other available research compound.

SS-31 Dosing and Research Protocols

The FDA-approved dosing for elamipretide (Forzinity) in Barth syndrome is 40 mg subcutaneously once daily in patients weighing 30 kg or more. This is the most rigorously validated dose, established through the TAZPOWER Phase 3 trial. Research-grade SS-31 from peptide suppliers is not the same product as the approved pharmaceutical — it is sold for laboratory use and is not subject to the same manufacturing oversight.

For researchers working with lyophilized SS-31, reconstitution follows standard peptide handling procedures. Use bacteriostatic water as the reconstitution solvent. Direct the stream against the vial wall, not onto the lyophilized cake. Allow the peptide to dissolve with gentle swirling — never shake. Our peptide reconstitution guide covers the full step-by-step process. For dosing calculations, the peptide calculator guide provides conversion formulas between milligrams and volume measurements.

Storage of SS-31 requires attention to the peptide’s stability characteristics. Unreconstituted vials should be stored at -20°C or below for long-term storage, or refrigerated at 2-8°C for shorter periods. Once reconstituted, the solution should be refrigerated and used within 28 days. SS-31’s tetrapeptide structure makes it relatively stable compared to larger peptides, but light exposure and repeated freeze-thaw cycles should still be avoided. For comprehensive storage guidance, see our peptide storage guide.

SS-31 Safety Profile in Clinical Research

Across the Phase 2 and Phase 3 programs, SS-31 (Elamipretide) has accumulated a substantial human safety database, which distinguishes it from most research peptides that have little or no controlled clinical safety data. In the TAZPOWER trial for Barth syndrome, the most frequently reported adverse events were injection site reactions among participants receiving subcutaneous dosing. These reactions were generally described as mild to moderate and did not typically require treatment discontinuation. Other adverse events reported at low frequency included nausea, diarrhea, and headache, without a clear pattern distinguishing active treatment from placebo across the trial population.

In the EMBRACE-STEMI cardiac trial, intravenous administration of SS-31 during acute reperfusion was not associated with a meaningful increase in serious adverse events relative to placebo, supporting short-term tolerability in an acute clinical setting. No signal of hepatotoxicity, nephrotoxicity, or clinically significant QT prolongation emerged across the published trial data, a notable finding given that some mitochondria-targeted compounds can interact with cardiac ion channels. The ReCLAIM and ReNEW trials in dry age-related macular degeneration similarly reported injection site reactions as the dominant adverse event, with no significant increase in systemic serious adverse events compared to placebo.

Long-term safety data remains more limited than short-term data, reflecting the relatively recent clinical development history of the compound. Most published safety information comes from patient populations with underlying mitochondrial disease or cardiac pathology, and these safety profiles may not directly generalize to healthy research subjects. As with any investigational compound, researchers working with SS-31 in laboratory settings should follow established protocols for sterile handling, accurate dosing, and careful observation of injection sites for local reactions, documenting any deviations from expected tolerability patterns.

The table below summarizes the adverse event patterns reported across the three major SS-31 clinical research programs to date.

Overall, the published safety record for SS-31 compares favorably to many experimental compounds in the mitochondrial research space, largely because of its multiple completed Phase 2 and Phase 3 trials. Researchers should nonetheless treat this compound like any other investigational agent: safety monitoring, proper storage, and adherence to reconstitution guidelines remain essential regardless of the existing human trial data. This safety profile should be considered alongside efficacy data when designing research protocols involving SS-31.

The Aging Mitochondria Problem: Why SS-31 Research Matters

The scientific case for SS-31 rests on a well-established biological reality: mitochondrial function declines with age, and this decline contributes to virtually every age-related disease. Published research shows that cardiolipin content in heart mitochondria decreases by approximately 20-30% between young adulthood and old age. This decline correlates with reduced ATP production capacity, increased ROS generation, and decreased efficiency of the electron transport chain.

The consequences extend beyond energy production. Damaged mitochondria release pro-inflammatory signals (DAMPs) that activate innate immune pathways — contributing to the chronic low-grade inflammation known as “inflammaging.” Mitochondrial dysfunction also triggers apoptotic and necrotic cell death pathways, contributes to stem cell exhaustion, and impairs the cellular repair mechanisms that maintain tissue homeostasis. The published literature on mitochondrial aging represents one of the most active areas of gerontology research.

SS-31’s ability to directly stabilize cardiolipin makes it uniquely positioned in this research space. Rather than addressing downstream consequences of mitochondrial dysfunction (scavenging ROS, supplementing NAD+, providing CoQ10), SS-31 addresses a root structural cause. The Phase 2 data showing improved ATP synthesis in aged human skeletal muscle provides direct evidence that this structural approach translates to functional bioenergetic improvement in living tissue.

Researchers studying mitochondrial biology alongside other age-related mechanisms may also explore how SS-31 intersects with the broader longevity peptide landscape. While SS-31 targets mitochondrial structure, MOTS-C targets mitochondrial-derived metabolic signaling, epitalon targets telomere maintenance, and GHK-Cu targets tissue regeneration through gene expression modulation. Each addresses a different hallmark of aging, and the research interest increasingly focuses on how these mechanisms interact.

The practical significance of mitochondrial decline extends to exercise capacity, cognitive function, immune surveillance, and stem cell maintenance — virtually every tissue function that deteriorates with age has a mitochondrial component. Published data from the National Institute on Aging’s Interventions Testing Program and related longitudinal studies consistently identify mitochondrial function as one of the strongest predictors of biological aging rate. SS-31’s ability to restore electron transport chain efficiency in aged human tissue, demonstrated with quantitative ³¹P-MRS measurements, provides one of the few examples of a pharmacological intervention reversing a biomarker of mitochondrial aging in a controlled human study.

For researchers designing comprehensive aging protocols, the question is not whether to address mitochondrial function, but which aspect to target. SS-31 addresses the structural foundation — the membrane architecture that makes electron transport possible. MOTS-C addresses the metabolic signaling that coordinates cellular energy use. NAD+ precursors address the cofactor availability that fuels specific enzymatic reactions. These represent non-overlapping interventions that could theoretically be combined for synergistic mitochondrial support, though no published clinical data exists for multi-compound mitochondrial protocols.

SS-31 and Cardiac Research: The Heart-Mitochondria Connection

The heart is the most mitochondria-dense organ in the body — cardiomyocytes contain approximately 5,000-8,000 mitochondria per cell, comprising roughly 30% of the cell’s total volume. This extraordinary mitochondrial density reflects the heart’s continuous energy demands: the adult heart produces and consumes approximately 6 kg of ATP per day to sustain uninterrupted contraction. Any decline in mitochondrial efficiency directly impacts cardiac function — which is why cardiac diseases are among the most active research areas for SS-31.

The EMBRACE-STEMI trial demonstrated the concept in acute settings. During a heart attack, ischemia-reperfusion injury causes massive mitochondrial dysfunction: ROS flood the cell, cardiolipin is oxidized, and the mitochondrial permeability transition pore opens, triggering cell death cascades. By stabilizing cardiolipin during reperfusion, SS-31 may protect cardiomyocytes from the secondary damage that occurs when blood flow is restored — damage that often causes more injury than the initial ischemia itself.

Beyond acute events, chronic heart failure involves progressive mitochondrial dysfunction that correlates with disease severity. Published research using cardiac MRI and functional assessments has shown that elamipretide improves left ventricular end-systolic and end-diastolic volumes in heart failure patients — structural changes that indicate improved cardiac function. For researchers studying the intersection of mitochondrial biology and cardiovascular health, SS-31 provides the most clinically validated pharmacological tool for mitochondrial membrane protection.

The implications for age-related cardiac decline are also significant. Even in the absence of clinical heart failure, aging hearts show reduced mitochondrial function, decreased cardiolipin content, and impaired ATP production capacity. The Phase 2 skeletal muscle data showing improved ATP synthesis in older adults suggests that SS-31 may have similar restorative effects in cardiac tissue — an area of active investigation in gerontology research.

This cardiac application complements rather than overlaps with other cardiovascular peptides. BPC-157 is studied for its effects on angiogenesis and tissue repair through different signaling pathways. Thymosin Alpha-1 modulates immune function relevant to inflammatory cardiac conditions. SS-31’s unique contribution is structural protection of the energy-producing machinery itself — a mechanism no other available peptide addresses.

Further Reading

For additional peer-reviewed research, see: PubMed research on elamipretide and cardiolipin.

Understanding ss-31 is essential for researchers navigating this rapidly evolving field in 2026.

Frequently Asked Questions

What is SS-31 and how is it different from other mitochondrial supplements?

SS-31 (Elamipretide) is a synthetic tetrapeptide that concentrates in the inner mitochondrial membrane and stabilizes cardiolipin — the phospholipid essential for electron transport chain function. Unlike CoQ10, NAD+ precursors, or other mitochondrial supplements that provide substrates or cofactors, SS-31 protects the physical structures that make energy production possible. It has Phase 2/3 clinical trial data and an FDA approval for Barth syndrome.

Is SS-31 the same as MOTS-C?

No. SS-31 is a synthetic peptide that stabilizes mitochondrial membrane structure through cardiolipin binding. MOTS-C is an endogenous mitochondrial-derived peptide that activates AMPK metabolic signaling pathways. They target completely different aspects of mitochondrial biology and are considered complementary rather than interchangeable.

Is SS-31 FDA approved?

Elamipretide received FDA approval for Barth syndrome under the brand name Forzinity at a dose of 40 mg daily subcutaneously. It remains investigational for all other indications including heart failure, age-related macular degeneration, and primary mitochondrial myopathy. Research-grade SS-31 from suppliers like PSPeptides is not the same as the approved pharmaceutical product.

What clinical evidence exists for SS-31?

SS-31 has been evaluated in Phase 2/3 trials for Barth syndrome (TAZPOWER — positive, led to FDA approval), heart failure (EMBRACE-STEMI — safety and signals of efficacy), skeletal muscle aging (improved ATP synthesis measured by ³¹P-MRS), and dry AMD (ReCLAIM/ReNEW — structural preservation signals). This represents more human clinical data than any other mitochondria-targeted peptide.

All PSPeptides products are sold exclusively for research and laboratory use.